ClinicalTrials.Veeva

Menu

Bacterial Properties With LoFric® Catheters During Clean Intermittent Catheterization

Nationwide Children's Hospital logo

Nationwide Children's Hospital

Status and phase

Withdrawn
Phase 2
Phase 1

Conditions

Urinary Retention
Neurogenic Bladder

Treatments

Device: LoFric® catheters during clean intermittent catheterization

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT01305681
IRB10-00458

Details and patient eligibility

About

The primary objective of our study is to examine characteristics of bacteria that are discovered in urine from pediatric patients that utilize either LoFric® or non-LoFric® catheters for self intermittent catheterization. The investigators hypothesize that the hydrophilic nature of the LoFric® catheter will alter the microbial environment and reduce clinically significant urinary tract infections in patients with neurogenic bladder compared to a similar population using standard catheters.

Secondary outcomes will be comparing the incidence of clinical urinary tract infections between patients that use standard catheters and those that use LoFric catheters.

Lastly, patient satisfaction using LoFric catheters compared to standard catheters will be assessed.

Full description

The investigators will randomize patients with neurogenic bladder into 2 groups after the have been matched for age, gender and mobility.

The first group will continue with their current intermittent catheterization system (a non-LoFric® catheter) while the second group will receive sufficient LoFric® catheters to complete the study. The investigators will collect the urine at the start of the study, and then at 3, 6, 12, and 18 months and sent for culture. If a child develops a urinary tract infection, the investigators will have the patient collect the urine and the urine will be cultured and the organism will be identified.

Using an existing bladder cell line, the investigators will inoculate the bladder cells with any bacteria that grows from any sample and then determine the interleukin-6 response of the bladder cell line following inoculation with the bacteria. This will determine if the initiate a high or low cytokine response which the investigators have correlated to clinical risk of symptomatic urinary tract infection

The investigators will provide a patient satisfaction survey at the start of the study, prior to randomization and at the completion of the study to determine satisfaction with LoFric® catheters.

Sex

All

Ages

Under 35 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients who perform clean intermittent catheterization on a regular basis

Exclusion criteria

  • Patients on daily continuous antibiotic therapy

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

0 participants in 1 patient group

LoFric® catheters
Active Comparator group
Description:
LoFric® catheters during clean intermittent catheterization will be compared to non-LoFric® catheters during clean intermittent catheterization
Treatment:
Device: LoFric® catheters during clean intermittent catheterization

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems